Glioblastoma Multiforme (GBM) Treatment Market Summary

The global glioblastoma multiforme (GBM) treatment market was valued at USD 3.72 billion in 2024 and is expected to reach USD 7.87 billion by 2033, expanding at a CAGR of 8.68% from 2025 to 2033. Market growth is primarily driven by the rising prevalence of GBM and the substantial clinical burden associated with this aggressive brain cancer.

GBM incidence is increasing globally due to improved diagnostic capabilities and a notable rise in actual case numbers. The growing aging population further intensifies this trend, as the risk of developing GBM increases significantly with age. As geriatric populations expand worldwide, healthcare systems face mounting challenges, reinforcing the critical need for more effective therapies and advanced care strategies.

Recent data from leading healthcare institutions underscore the escalating burden of GBM. In December 2024, Parkway Cancer Centre in Singapore reported nearly 100 new GBM cases per year, highlighting the pressure on advanced neuro-oncology services. Standard GBM management typically requires a multidisciplinary approach involving surgical resection followed by combined radiotherapy and chemotherapy. Despite this rigorous treatment pathway, recurrence within months remains common, demonstrating the limitations of existing therapies. The center’s findings emphasize the importance of ongoing advancements in personalized medicine, including genomics and immunotherapy, to better address GBM complexity and improve patient outcomes.

Order a free sample PDF of the Glioblastoma Multiforme Treatment Market Intelligence Study, published by Grand View Research.

Key Market Trends & Insights

• North America accounted for 39.87% of the global market share in 2024.
• The U.S. GBM treatment market is projected to grow significantly throughout the forecast period.
• By treatment type, the surgery segment dominated with a 32.71% share in 2024.
• By end use, hospitals and clinics held the largest market share in 2024.

Market Size & Forecast

• 2024 Market Size: USD 3.72 Billion
• 2033 Projected Market Size: USD 7.87 Billion
• CAGR (2025–2033): 8.68%
• Largest Market (2024): North America
• Fastest Growing Region: Asia Pacific

Key GBM Treatment Company Insights

Leading companies are heavily investing in research and development to create innovative therapies and strengthen their competitive position:

• Merck & Co., Inc. and F. Hoffmann-La Roche Ltd. are advancing targeted therapies and immuno-oncology treatments focused on molecular precision and improved survival rates.
• Amgen, Inc. and Pfizer Inc. are developing novel biologics and combination regimens designed to penetrate the blood–brain barrier and enhance therapeutic effectiveness.
• Teva Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. continue to expand access to essential treatments through generic temozolomide and supportive care products.
• Arbor Pharmaceuticals, LLC (Azurity) and Amneal Pharmaceuticals are developing formulation innovations to improve drug delivery and patient compliance.
• Karyopharm Therapeutics, Inc. and Sumitomo Dainippon Pharma Oncology, Inc. are focused on next-generation small molecules and precision therapies.
  Collaborative clinical networks and global trial partnerships are playing a key role in accelerating new therapy approvals and strengthening the GBM treatment pipeline.

Leading GBM Treatment Companies

• Merck & Co., Inc.
• Teva Pharmaceutical
• Sun Pharma
• Amneal Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• Amgen, Inc.
• Pfizer Inc.
• Arbor Pharmaceuticals (Azurity)
• Karyopharm Therapeutics, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The glioblastoma multiforme treatment market is poised for robust growth through 2033 due to rising GBM incidence, expanding geriatric populations, and the urgent need for more effective therapies. Although surgery, radiotherapy, and chemotherapy remain the standard of care, high recurrence rates highlight major gaps in current treatment options. As a result, the industry is rapidly moving toward advanced, personalized approaches—including targeted therapies, immuno-oncology, and precision medicine. With North America leading in market share and Asia Pacific emerging as the fastest-growing region, companies are intensifying R&D, forming strategic collaborations, and introducing innovative therapeutic solutions. These developments collectively position the GBM treatment market for sustained advancement and improved patient outcomes in the coming years.